Ultragenyx Reaffirms 2023 Expected Total Revenue Guidance Of $425M-$450M
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical Inc. has reaffirmed its total revenue guidance for 2023, expecting to generate between $425 million and $450 million.
November 02, 2023 | 8:42 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ultragenyx Pharmaceutical Inc. (RARE) has reaffirmed its 2023 revenue guidance, which is expected to be between $425 million and $450 million.
Ultragenyx's reaffirmation of its 2023 revenue guidance is a neutral signal for the stock. It shows that the company is confident in its future performance, but it does not provide new information that could significantly move the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100